Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2021 June;112(3) > Minerva Medica 2021 June;112(3):322-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Medica 2021 June;112(3):322-8

DOI: 10.23736/S0026-4806.20.06817-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

How low is “low-flow” in aortic stenosis? A retrospective analysis of patients with true low-flow/low-gradient aortic stenosis undergoing TAVI

Tanja KÜCKEN 1, 2 , Christoph EDLINGER 1, 2, 3, Maki OKAMOTO 1, 2, Marwin BANNEHR 1, 2, Peter JIRAK 3, Michael LICHTENAUER 3, Anja HAASE-FIELITZ 1, 2, Florian KRIZANIC 4, Christian BUTTER 1, 2

1 Department of Cardiology, Heart Center Brandenburg, Bernau bei Berlin, Germany; 2 Brandenburg Medical School (MHB) Theodor Fontane, Neuruppin, Germany; 3 Department of Cardiology, Clinic of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria; 4 Department of Cardiology, Caritas Clinic Pankow Berlin, Berlin, Germany



BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a valuable treatment option for patients with reduced left ventricular ejection fraction (LVEF) and low-flow/low-gradient (LF/LG) aortic stenosis (AS). According to current literature, the presence of severe AS is unlikely in case of severely reduced LVEF and mean pressure gradient (meanPG) below 30 mmHg. However, a considerable number of patients presenting with typical clinical symptoms of severe AS, show gradients below 30 mmHg. We hypothesized, that these patients undergoing TAVI do have a measurable clinical benefit and an improved LVEF.
METHODS: In this single center retrospective cohort study, data from 1199 patients undergoing TAVI between 2013 and 2017 was analyzed. A 6-month follow-up was performed to assess changes in NT-proBNP, NYHA-class, and LVEF.
RESULTS: Thirty patients presented with LVEF<35%, an aortic valve area (AVA<1 cm2), and a meanPG below 30 mmHg. Mean logistic EuroSCORE II was 24.05±10.9. Most patients (56%) showed improved NYHA-class upon follow-up. NT-proBNP-levels decreased from 3.901 pg/mL IQR 10.880 to 1.491 pg/mL IQR 2.245 (P<0.001). LVEF increased from 30% IQR 6.25 to 40% IQR 15 (P<0.001).
CONCLUSIONS: Based on our findings TAVI represents a valuable treatment option even in patients with LF/LG AS and PGmean below 30mmHg.


KEY WORDS: Aortic valve stenosis; Transcatheter aortic valve replacement; Stroke volume

top of page